Follow us on LinkedIn Twitter


The shopping cart is empty
Knows our products
Knows our services
Knows our R+D

PROALT (Protein Alternatives SL)


ProAlt is young biotech company developing innovative products for colorectal cancer early diagnosis in blood and novel therapeutic antibodies for the treatment of colon, breast and melanoma metastatic tumors.


The company also offers its own manufactured recombinant proteins and antibodies, and different custom-tailored services in protein and antibodies design and manufacturing (CRO/CMO).

Special Offers

ProAlt news


Successful start of the clinical validation study of COLODETECT®, a blood-based diagnostic test for early detection of colorectal cancer by PROALT. View more



PROALT announces partnership with Fusion Antibodies to develop humanized antibodies for therapy of metastatic colon cancer. View more




ProAlt events

June 2019

BIO International Convention. Philadelphia, PA (USA) 3-6 June 2019.

View more



November 2019

BIOEUROPE. Hamburg, Germany. 11-13 November 2019.

View more



ProAlt new products

PRO-50078 Human Beta-2-Microglobulin


PRO-50077, PRO-50076, PRO-50075 Human Gelsolin Isoform A (GSN) N- or C-terminal half

AB-10011 Rabbit anti-GSN polyclonal antibody

MAB-010, MAB-011 Mouse Anti-GSN monoclonal antibodies


PRO-50074, PRO-50073, Human Ganglioside GM2 activator isoform 1 (GM2AP) recombinant protein

AB-10010 Rabbit anti- GM2AP, polyclonal antibody

MAB-008, MAB-009: Mouse Anti-GM2AP monoclonal antibodies

© Developed by Web4Bio